Genomic Health: Delivering on the promise of precision medicine
As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ portfolio of tests. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey.
The problem of waste in cancer therapeutics
More than $100 billion is spent each year on cancer drugs worldwide to improve the lives of men and women diagnosed with cancer1. However, with an average efficacy rate of only 25%2, most patients do not experience significant clinical benefit—resulting in more than $75 billion in annual spending on ineffective treatments. Review the data on the impact of Oncotype IQ on current cancer care costs.
The Oncotype DX Breast Recurrence Score results can save up to $49 million in short term health care costs for women with early-stage breast cancer3.